高フェニルアラニン血(Hyperphenylalaninemia):グローバル臨床試験レビュー(2014年上半期)

◆英語タイトル:Hyperphenylalaninemia Global Clinical Trials Review, H1, 2014
◆商品コード:GDHC2124CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年4月30日
◆ページ数:95
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Hyperphenylalaninemia Global Clinical Trials Review, H1, 2014

Summary

GlobalData’s clinical trial report, “Hyperphenylalaninemia Global Clinical Trials Review, H1, 2014″ provides data on the Hyperphenylalaninemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperphenylalaninemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperphenylalaninemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hyperphenylalaninemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Hyperphenylalaninemia 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Hyperphenylalaninemia Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Teijin Limited 32
Clinical Trial Overview of Teijin Limited 32
Takeda Pharmaceutical Company Limited 33
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 33
Sanofi 34
Clinical Trial Overview of Sanofi 34
AstraZeneca PLC 35
Clinical Trial Overview of AstraZeneca PLC 35
Fuji Yakuhin Co., Ltd. 36
Clinical Trial Overview of Fuji Yakuhin Co., Ltd. 36
BioMarin Pharmaceutical Inc. 37
Clinical Trial Overview of BioMarin Pharmaceutical Inc. 37
Sanwa Kagaku Kenkyusho Co., Ltd. 38
Clinical Trial Overview of Sanwa Kagaku Kenkyusho Co., Ltd. 38
Nuon Therapeutics, Inc. 39
Clinical Trial Overview of Nuon Therapeutics, Inc. 39
Japan Tobacco Inc. 40
Clinical Trial Overview of Japan Tobacco Inc. 40
BioCryst Pharmaceuticals, Inc. 41
Clinical Trial Overview of BioCryst Pharmaceuticals, Inc. 41
Clinical Trial Overview of Top Institutes / Government 42
Kyushu University 42
Clinical Trial Overview of Kyushu University 42
University of Otago 43
Clinical Trial Overview of University of Otago 43
China Medical University Hospital 44
Clinical Trial Overview of China Medical University Hospital 44
National Cerebral and Cardiovascular Center 45
Clinical Trial Overview of National Cerebral and Cardiovascular Center 45
Tottori University Hospital 46
Clinical Trial Overview of Tottori University Hospital 46
Fukushima Medical University 47
Clinical Trial Overview of Fukushima Medical University 47
The University of Texas Health Science Center at Houston 48
Clinical Trial Overview of The University of Texas Health Science Center at Houston 48
The Medical Center Leeuwarden 49
Clinical Trial Overview of The Medical Center Leeuwarden 49
Juntendo University School of Medicine 50
Clinical Trial Overview of Juntendo University School of Medicine 50
Midorigaoka Hospital 51
Clinical Trial Overview of Midorigaoka Hospital 51
Five Key Clinical Profiles 52
Appendix 93
Abbreviations 93
Definitions 93
Research Methodology 94
Secondary Research 94
About GlobalData 95
Contact Us 95
Disclaimer 95
Source 95

List of Tables
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hyperphenylalaninemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Hyperphenylalaninemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Hyperphenylalaninemia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Hyperphenylalaninemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Hyperphenylalaninemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Hyperphenylalaninemia Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Hyperphenylalaninemia Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Hyperphenylalaninemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Teijin Limited, 2014* 32
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 33
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 34
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 35
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fuji Yakuhin Co., Ltd., 2014* 36
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by BioMarin Pharmaceutical Inc., 2014* 37
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanwa Kagaku Kenkyusho Co., Ltd., 2014* 38
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Nuon Therapeutics, Inc., 2014* 39
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Japan Tobacco Inc., 2014* 40
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by BioCryst Pharmaceuticals, Inc., 2014* 41
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyushu University, 2014* 42
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Otago, 2014* 43
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by China Medical University Hospital, 2014* 44
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cerebral and Cardiovascular Center, 2014* 45
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Tottori University Hospital, 2014* 46
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fukushima Medical University, 2014* 47
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas Health Science Center at Houston, 2014* 48
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The Medical Center Leeuwarden, 2014* 49
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Juntendo University School of Medicine, 2014* 50
Hyperphenylalaninemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Midorigaoka Hospital, 2014* 51

List of Figures
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hyperphenylalaninemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Hyperphenylalaninemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Hyperphenylalaninemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Hyperphenylalaninemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hyperphenylalaninemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hyperphenylalaninemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hyperphenylalaninemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Hyperphenylalaninemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Hyperphenylalaninemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Hyperphenylalaninemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 94

【レポートのキーワード】

高フェニルアラニン血、治験、臨床試験

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[高フェニルアラニン血(Hyperphenylalaninemia):グローバル臨床試験レビュー(2014年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆